Abstract Library

#3661 Blood liver enzyme levels correlate with hepatic tumor burden in advanced neuroendocrine tumors

Introduction: Abnormal levels of blood liver enzymes, including hepatic liver enzymes alanine aminotransferase (ALT) or aspartate aminotransferase (AST), and cholestatic liver enzymes alkaline phosphatase (ALP) or gamma-glutamyl transpeptidase (GGT)can be found in some patients with advanced neuroendocrine tumors (NETs), but the clinical relevance is less understood.

Conference:

Presenting Author:

Authors: Chen L, Jumai N, Liu M, He Q, Lin Y,

Keywords: neuroendocrine tumor, hepatic tumor burden, liver enzyme, overall survival,

#3553 Gamma-glutamyltransferase as an indicator of hepatic tumor burden in neuroendocrine tumors

Introduction: In patients with neuroendocrine tumors (NETs) and liver metastasis, elevation of gamma-glutamyltransferase (GGT) is considered to be a sign of hepatic progression. However, there are no data supporting this assumption.

Conference:

Presenting Author: Schmidt B

Authors: Schmidt B, Leiderer M, Amin T, Viol F, Adam G,

Keywords: gamma glutamyltransferase, hepatic tumor burden, neuroendocrine tumor, liver metastasis, biomarker,

#3127 The role of somatostatin receptor scintigraphy in predicting treatment response of somatostatin analogues in pancreatic neuroendocrine tumors

Introduction: Over 50% of pancreatic neuroendocrine tumors (pNETs) are diagnosed with distant metastasis, and somatostatin analogues (SSAs) are considered one of the most popular therapies in metastatic pNETs. However, it is still controversial about the role of somatostatin receptor scintigraphy (SRS) in response to SSA.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Gao H,

Keywords: pancreatic neuroendocrine tumor, somatostatin analogues, somatostatin receptor scintigraphy, response to treatment,

#2883 Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study

Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Lamarca A, Barriuso J, Castaño A,

Keywords: Bayesian model, octreotide, lanreotide, progression-free survival, efficacy,

#2208 High Hepatic Tumor Burden and History of Cardiovascular Comorbidities Are Associated with Carcinoid Heart Disease: A Multicenter and Multinational Study

Introduction: While 5HT is considered the main causative agent for carcinoid heart disease (CHD, not all pts with elevated 24h-urinary 5HIAA (u5HIAA) develop CHD.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Riechelmann R

Authors: Riechelmann R, Mesquita M, Alves C, Silva C, Soeiro M,

Keywords: carcinoid heart disease, neuroendocrine, prognostic, carcinoid syndrome,